Category Archives: Pr Newswire

STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central Asia and the Middle East This partnership for the osteoporosis and cancer-related molecule builds on the two company’s existing strategic alliance in Europe. The first product launched through […]

STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central Asia and the Middle East This partnership for the osteoporosis and cancer-related molecule builds on the two company’s existing strategic alliance in Europe. The first product launched through […]

— Lead Program, BPT567, will be the first PD1-IL18 immunoconjugate to enter the clinic; Phase 1/2a study in solid tumors expected to begin in 2H 2024 – — Financing led by Johnson & Johnson with participation by new and existing investors– BASEL, Switzerland and SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) — Bright Peak Therapeutics, […]

LINKÖPING, Sweden, June 11, 2024 /PRNewswire/ — Following the Swedish Tire Safety Council’s alarming report on wheel detachment incidents, NIRA Dynamics reaffirms the value of its pioneering Loose Wheel Indicator (LWI) technology. Established in the market since 2017 and currently enhancing over 1 million vehicles, including Audi’s fleet, LWI represents a significant leap in automotive safety, […]

Today, GN has decided to gradually wind-down its Elite and Talk product lines to further increase focus and resources on more attractive parts of GN’s business. As communicated at the Capital Market Day in May 2024, GN is striving to build leading businesses in attractive markets and by this grow with healthy margins and ensure […]

Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma Egham, UK and Copenhagen, Denmark – 11 June, 2024 – Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically differentiated, niche pharmaceutical products […]

SEOUL, South Korea, June 11, 2024 /PRNewswire/ — Hugel Inc, a global total medical aesthetics company, announced that the Administrative Law Judge (ALJ) for its U.S. International Trade Commission(ITC) investigation issued an initial determination on June 10th (local time) finding that “there is no violation of Section 337” based on Medytox’s allegation of unfair practices […]

SUZHOU, China, and ROCKVILLE, Md., June 11, 2024 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Product Administration (NMPA) has approved a global registrational Phase III study […]

SAN DIEGO and IRVINE, Calif. and HONG KONG, June 11, 2024 /PRNewswire/ — On June 11, the President of the Reproductive Science Medical Center (RSMC) in the United States successfully concluded his visit to Asia. During the week-long trip, the President engaged in one-on-one meetings with guests from various regions, providing in-depth explanations of reproductive […]

SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 158,000 shares of its common stock to nine new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 […]